Clinical study of switching from pemafibrate IR to XR

Clinical study of switching from pemafibrate IR to XR - Clinical study of switching from pemafibrate IR to XR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053992

Enrollment

Registered

2024-03-28

Start date

2023-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertriglyceridemia while taking pemafibrate IR

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Triglyceridemia while taking pemafibrate IR

Exclusion criteria

Exclusion criteria: Patients who were deemed not appropriate to participate in this study by doctor

Design outcomes

Primary

Measure	Time frame
TG	—

Secondary

Measure	Time frame
1) LDL, HDL, T-cho 2) sCr, eGFR , AST, ALT 3)Remnant-Like Particle, fatty acid fractionation 4) oxidized LDL, hs-CPR 5) side effects	—

Countries

Japan

Contacts

Public ContactMitsue Akiyama

Sekino Laboratory Department of Research

skn-np@sekino-hospital.com03-3986-5501

Outcome results